BJA Advance Access originally published online on February 11, 2005
British Journal of Anaesthesia 2005 94(5):592-595; doi:10.1093/bja/aei094
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CASE REPORT |
Recombinant factor VIIa for life-threatening post-partum haemorrhage
Department of Anaesthesia and Intensive Care, Helsinki University Hospital, Finland
* Corresponding author. E-mail: jouni.ahonen{at}fimnet.fi
The treatment of life-threatening post-partum haemorrhage (PPH) still remains challenging, and hysterectomy may be required to control the bleeding. We present 12 cases of severe PPH treated with recombinant factor VIIa (rFVIIa). We briefly describe the causes of the haemorrhage and the medical and surgical interventions before rVIIa administration. In 11 women there was a partial or good response to rFVIIa administration, while in one there was no response. In the four women undergoing a subsequent selective arterial embolization, the bleeding was significantly reduced although not completely stopped. From our experience with these 12 cases, and from previously reported cases, the use of rFVIIa may be of benefit in life-threatening PPH. However, treatment with rFVIIa, in addition to standard surgical and medical interventions, may not be definitive in every patient and a selective arterial embolization may be needed.
This article is accompanied by the Editorial.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. E. Phillips, C. McLintock, W. Pollock, S. Gatt, P. Popham, G. Jankelowitz, R. Ogle, and P. A. Cameron Recombinant Activated Factor VII in Obstetric Hemorrhage: Experiences from the Australian and New Zealand Haemostasis Registry Anesth. Analg., December 1, 2009; 109(6): 1908 - 1915. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Hedner and M. Ezban Recent advances in clot biology and assessment of clotting Trauma, October 1, 2008; 10(4): 261 - 270. [Abstract] [PDF] |
||||
![]() |
M. Ranucci, G. Isgro, G. Soro, D. Conti, and B. De Toffol Efficacy and Safety of Recombinant Activated Factor VII in Major Surgical Procedures: Systematic Review and Meta-analysis of Randomized Clinical Trials Arch Surg, March 1, 2008; 143(3): 296 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ridley, B. Taylor, and K. Gunning Medical management of bleeding in critically ill patients CEACCP, August 1, 2007; 7(4): 116 - 121. [Full Text] [PDF] |
||||
![]() |
L. Morante, E. V. Guasch, F. Palacio, and F. Gilsanz Activated Recombinant Factor VII to Reverse Oral Anticoagulants for Emergent Cesarean Delivery. Anesth. Analg., June 1, 2006; 102(6): 1902 - 1903. [Full Text] [PDF] |
||||
![]() |
B. Brenner, R. Hoffman, D. Balashov, E. Shutluko, S. Culic, and E. Nizamoutdinova Control of Bleeding Caused by Thrombocytopenia Associated With Hematologic Malignancy: An Audit of the Clinical Use of Recombinant Activated Factor VII Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 401 - 410. [Abstract] [PDF] |
||||
![]() |
A. J. Butwick, E. T. Riley, J. Ahonen, and R. Jokela Recombinant factor VIIa for life-threatening post-partum haemorrhage Br. J. Anaesth., October 1, 2005; 95(4): 558 - 558. [Full Text] [PDF] |
||||





